Orchard Therapeutics PLC Performance
| ORTXDelisted Stock | USD 5.27 0.01 0.19% |
The company holds a Beta of 0.48, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Orchard Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Orchard Therapeutics is expected to be smaller as well. Orchard Therapeutics PLC right now holds a risk of 0.0%. Please check Orchard Therapeutics PLC maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to decide if Orchard Therapeutics PLC will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Orchard Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Orchard Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 85 M |
Orchard |
Orchard Therapeutics Relative Risk vs. Return Landscape
If you would invest 527.00 in Orchard Therapeutics PLC on September 4, 2024 and sell it today you would earn a total of 0.00 from holding Orchard Therapeutics PLC or generate 0.0% return on investment over 90 days. Orchard Therapeutics PLC is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Orchard, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Orchard Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orchard Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orchard Therapeutics PLC, and traders can use it to determine the average amount a Orchard Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ORTX |
Based on monthly moving average Orchard Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orchard Therapeutics by adding Orchard Therapeutics to a well-diversified portfolio.
Orchard Therapeutics Fundamentals Growth
Orchard Stock prices reflect investors' perceptions of the future prospects and financial health of Orchard Therapeutics, and Orchard Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orchard Stock performance.
| Return On Equity | -0.72 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (3.43) % | |||
| Current Valuation | 302.52 M | |||
| Shares Outstanding | 22.76 M | |||
| Price To Earning | (8.06) X | |||
| Price To Book | 4.74 X | |||
| Price To Sales | 17.41 X | |||
| Revenue | 21.84 M | |||
| EBITDA | (99.34 M) | |||
| Cash And Equivalents | 170.89 M | |||
| Cash Per Share | 1.35 X | |||
| Total Debt | 58.09 M | |||
| Debt To Equity | 0.41 % | |||
| Book Value Per Share | 3.53 X | |||
| Cash Flow From Operations | (93.32 M) | |||
| Earnings Per Share | (4.10) X | |||
| Total Asset | 218.91 M | |||
| Retained Earnings | (900.88 M) | |||
| Current Asset | 300.47 M | |||
| Current Liabilities | 46.52 M | |||
About Orchard Therapeutics Performance
Evaluating Orchard Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Orchard Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Orchard Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. Orchard Therapeutics is traded on NASDAQ Exchange in the United States.Things to note about Orchard Therapeutics PLC performance evaluation
Checking the ongoing alerts about Orchard Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Orchard Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orchard Therapeutics is not yet fully synchronised with the market data | |
| Orchard Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 21.84 M. Net Loss for the year was (72.92 M) with loss before overhead, payroll, taxes, and interest of (76.52 M). | |
| Orchard Therapeutics PLC currently holds about 170.89 M in cash with (93.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.35. | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Hookipa Pharma price target lowered to 7 from 24 at JMP Securities - TipRanks |
- Analyzing Orchard Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orchard Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Orchard Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orchard Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orchard Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orchard Therapeutics' stock. These opinions can provide insight into Orchard Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Orchard Stock
If you are still planning to invest in Orchard Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orchard Therapeutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |